140 Participants Needed

PET/CT Scan with Tracers for Prostate Cancer

Recruiting at 2 trial locations
AJ
DS
Overseen ByDavid Schuster, MD
Age: 18+
Sex: Male
Trial Phase: Phase 2
Sponsor: Emory University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This phase II trial studies how well a positron emission tomography (PET)/computed tomography (CT) scan using fluciclovine F18 compared with a PET/CT scan with 68Ga-PSMA works in planning radiation treatments and enhancing outcomes in patients with prostate adenocarcinoma. Fluciclovine F18 and 68Ga-PSMA are types of tracers, called radiotracers, that are injected and can accumulate in tumor cells to develop images of them during a PET/CT scan. It is not yet known whether giving fluciclovine F18 or 68Ga-PSMA may work better in planning radiation treatments and enhancing outcomes in patients with prostate adenocarcinoma.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Fluciclovine F18, Axumin, Gallium Ga68-labeled PSMA-11 for prostate cancer?

Research shows that PET imaging with tracers like 18F-fluciclovine and PSMA-targeted agents, such as Gallium Ga68-labeled PSMA-11, improves disease detection rates and influences treatment planning for prostate cancer. These tracers are effective in identifying prostate cancer and have been incorporated into clinical guidelines, with early data suggesting improved patient outcomes.12345

Is the PET/CT scan with tracers for prostate cancer safe for humans?

The PET/CT scan using tracers like Fluciclovine F18 and Gallium Ga68-labeled PSMA-11 has been studied for safety, and these tracers are generally considered safe for clinical use. They have been approved by the FDA and are used in clinical settings, indicating a favorable safety profile.12678

How does the PET/CT scan with tracers for prostate cancer differ from other treatments?

The PET/CT scan with tracers for prostate cancer is unique because it uses specific tracers like 68Ga-PSMA-11 and 18F-PSMA-11, which are designed to target prostate-specific membrane antigen (PSMA), making it highly sensitive and specific for detecting prostate cancer. This imaging method is particularly useful for identifying both primary tumors and metastatic lesions, offering a more precise diagnosis compared to traditional imaging techniques.136910

Research Team

AJ

Ashesh Jani, MD, MSEE

Principal Investigator

Emory University

Eligibility Criteria

This trial is for men with prostate adenocarcinoma who've had surgery but still have detectable PSA levels, no signs of metastasis outside the pelvis or in bones, and can perform daily activities (ECOG 0-2). They must be willing to undergo pelvic radiotherapy and not have other recent cancers or severe illnesses like heart failure, infections needing IV antibiotics, severe lung disease, AIDS, or conditions that prevent radiation therapy.

Inclusion Criteria

I am able to get out of my bed or chair and move around.
I had surgery to remove my prostate due to adenocarcinoma.
No definitive findings for skeletal metastasis on technetium 99-m methyl diphosphonate (MDP) or F-18 PET bone scan
See 3 more

Exclusion Criteria

I do not have severe recent heart issues, infections needing IV antibiotics, severe lung problems, or AIDS.
I cannot have certain PET-CT scans due to my condition.
My cancer has spread to other parts of my body, confirmed by imaging or biopsy.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Imaging and Treatment Planning

Participants receive either fluciclovine F18 or 68Ga-PSMA intravenously and undergo PET/CT scans to plan radiation treatments

1-2 weeks
1 visit (in-person)

Radiation Treatment

Radiation treatment is administered based on PET/CT imaging results

6-8 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 5 years
Every 6 months

Treatment Details

Interventions

  • Fluciclovine F18
  • Gallium Ga68-labeled PSMA-11
Trial Overview The study compares two types of PET/CT scans using different tracers—Fluciclovine F18 and Ga68-labeled PSMA—to see which one is better at guiding radiation treatment plans for prostate cancer. The goal is to find out if one tracer leads to improved outcomes over the other in patients post-prostatectomy.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm I (fluciclovine F18, PET/CT)Experimental Treatment3 Interventions
Patients receive fluciclovine F18 IV and undergo positron emission tomography (PET)/computed tomography (CT) over 30 minutes.
Group II: Arm II (68Ga-PSMA, PET/CT)Active Control3 Interventions
Patients receive gallium Ga68-labeled PSMA-11 IV, wait 60 minutes, then undergo positron emission tomography (PET)/computed tomography (CT) over 30 minutes.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Emory University

Lead Sponsor

Trials
1,735
Recruited
2,605,000+

Telix Pharmaceuticals (Innovations) Pty Limited

Industry Sponsor

Trials
23
Recruited
2,400+

National Institutes of Health (NIH)

Collaborator

Trials
2,896
Recruited
8,053,000+

Telix International Pty Ltd

Industry Sponsor

Trials
19
Recruited
1,300+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

Findings from Research

The PET tracer 18F-PSMA 1007 was found to be safe and well tolerated in both healthy volunteers and prostate cancer patients, with no serious adverse events reported during the study.
In terms of diagnostic effectiveness, 18F-PSMA 1007 demonstrated high accuracy in detecting prostate cancer, achieving a sensitivity of 80% and a positive predictive value of 100% in patients with untreated preoperative prostate cancer.
Phase I/IIa trial of 18F-prostate specific membrane antigen (PSMA) 1007 PET/CT in healthy volunteers and prostate cancer patients.Tateishi, U., Kimura, K., Tsuchiya, J., et al.[2023]
PET imaging using radiotracers like 11C-choline and 18F-fluciclovine has become crucial in evaluating prostate cancer, significantly improving disease detection rates compared to traditional imaging methods like CT and MRI.
New PSMA-targeting PET radiotracers, such as 68-Ga-PSMA-11 and 18F-DCFPyL, have been approved by the FDA, indicating their efficacy in treatment planning and potential to enhance patient outcomes in prostate cancer management.
PET Imaging for Prostate Cancer.Savir-Baruch, B., Werner, RA., Rowe, SP., et al.[2021]
In a study of 24 patients with primary prostate cancer, Ga-PSMA-11 PET/CT demonstrated a high detection rate of 95.8%, confirming its effectiveness in identifying cancerous lesions.
Dynamic PET/CT imaging showed that Ga-PSMA-11 accumulation in prostate cancer lesions increased over time, suggesting its potential for enhancing treatment strategies targeting PSMA.
68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer.Sachpekidis, C., Kopka, K., Eder, M., et al.[2022]

References

Phase I/IIa trial of 18F-prostate specific membrane antigen (PSMA) 1007 PET/CT in healthy volunteers and prostate cancer patients. [2023]
PET Imaging for Prostate Cancer. [2021]
68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer. [2022]
Utility of PET to Appropriately Select Patients for PSMA-Targeted Theranostics. [2023]
Gross tumor volume delineation in primary prostate cancer on 18F-PSMA-1007 PET/MRI and 68Ga-PSMA-11 PET/MRI. [2022]
Validation of a [Al18F]PSMA-11 preparation for clinical applications. [2022]
Prostate Cancer-PET Imaging Update. [2023]
Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging. [2018]
Preparation and clinical translation of 99mTc-PSMA-11 for SPECT imaging of prostate cancer. [2020]
Synthesis and Evaluation of 99mTc-Labeled PSMA-Targeted Tracers Based on the Lys-Urea-Aad Pharmacophore for Detecting Prostate Cancer with Single Photon Emission Computed Tomography. [2023]